EGFR and neoplasm: Immunophenotyping demonstrated IDH1 mutation‐negative tumour cells with strong nuclear ATRX expression 47, 48 and EGFR overexpression 49, 50, confirming an expression profile consistent with IDH‐wildtype primary glioblastoma 51.